Menu Search
Equities

Conmed Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EC8:DUS

Conmed Corp

Actions
  • Price (EUR)41.00
  • Today's Change-1.20 / -2.84%
  • Shares traded--
  • 1 Year change-38.35%
  • Beta1.1738
Data delayed at least 15 minutes, as of Jul 18 2025 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

  • Revenue in USD (TTM)1.32bn
  • Net income in USD118.75m
  • Incorporated2020
  • Employees3.90k
  • Location
    Conmed Corp11311 Concept BoulevardLARGO 33773United StatesUSA
  • Phone+1 (727) 214-2974
  • Fax+1 (302) 655-5049
  • Websitehttps://www.conmed.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.